Charles River Laboratories (CRL) traded lower Tuesday as the market refocused on its strategic reshaping and near-term disruption. The company’s February 25, 2026 update on planned divestitures reset expectations for 2026 reported revenue growth to a decline of 5.0% to 3.5% (including the divestiture impact), a material step down from its prior view of at least flat to +1.5%. (ir.criver.com)

CRL said it signed definitive agreements to sell its CDMO and Cell Solutions businesses to GI Partners (primarily for contingent performance-based payments) and to divest certain European Discovery Services assets to IQVIA for about $145 million in cash plus up to $10 million in additional payments. CRL expects the transactions to close in the second quarter of 2026, subject to customary conditions. (ir.criver.com)

CRL said the planned divestitures are expected to reduce 2026 reported revenue by slightly more than $200 million and reduce organic growth guidance by more than 50 basis points, while generating at least 100 basis points of incremental non-GAAP operating margin improvement and adding about $0.10 to non-GAAP EPS for the partial year. Updated non-GAAP EPS guidance was lifted to $10.80–$11.30. (ir.criver.com)

Separately, WARN-tracking data shows a Massachusetts filing tied to Charles River Laboratories that lists 71 affected employees in Wilmington with a layoff date of April 24, 2026. While WARN notices don’t always translate into broader financial changes, the disclosure can add to investor concerns around restructuring execution and near-term disruption as the portfolio is streamlined. (warntracker.com)